Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies.
Anemia
/ diagnosis
Biomarkers
Biomarkers, Tumor
Combined Modality Therapy
/ adverse effects
Disease Management
Disease Susceptibility
Drug Development
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/ complications
Molecular Diagnostic Techniques
Molecular Targeted Therapy
Myeloproliferative Disorders
/ complications
Prognosis
Single-Cell Analysis
/ methods
Translational Research, Biomedical
Treatment Outcome
BCR-ABL1 mutants
genomic risk scores
interferon-alpha
luspatercept
non-JAK-STAT therapies
single-cell genomics
Journal
Hematological oncology
ISSN: 1099-1069
Titre abrégé: Hematol Oncol
Pays: England
ID NLM: 8307268
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
10
06
2020
accepted:
20
06
2020
pubmed:
28
6
2020
medline:
12
1
2021
entrez:
28
6
2020
Statut:
ppublish
Résumé
This review reflects the presentations and discussion at the 14th post-American Society of Hematology (ASH) International Workshop on Chronic Myeloproliferative Malignancies, which took place on the December 10 and 11, 2019, immediately after the 61st ASH Annual Meeting in Orlando, Florida. Rather than present a resume of the proceedings, we address some of the topical translational science research and clinically relevant topics in detail. We consider how recent studies using single-cell genomics and other molecular methods reveal novel aspects of hematopoiesis which in turn raise the possibility of new therapeutic approaches for patients with myeloproliferative neoplasms (MPNs). We discuss how alternative therapies could benefit patients with chronic myeloid leukemia who develop BCR-ABL1 mutant subclones following ABL1-tyrosine kinase inhibitor therapy. In MPNs, we focus on efforts beyond JAK-STAT and the merits of integrating activin receptor ligand traps, interferon-α, and allografting in the current treatment algorithm for patients with myelofibrosis.
Identifiants
pubmed: 32592408
doi: 10.1002/hon.2771
pmc: PMC8895354
mid: NIHMS1783486
doi:
Substances chimiques
Biomarkers
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
654-664Subventions
Organisme : Cancer Research UK
ID : 29034
Pays : United Kingdom
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA054174
Pays : United States
Informations de copyright
© 2020 The Authors. Hematological Oncology published by John Wiley & Sons Ltd.
Références
Bone Marrow Transplant. 2015 May;50(5):628-36
pubmed: 25665047
Blood. 2009 Mar 26;113(13):2895-901
pubmed: 18988864
Biomark Res. 2019 Jul 16;7:15
pubmed: 31346467
Clin Cancer Res. 2019 Aug 15;25(16):4898-4906
pubmed: 31061068
Lancet Haematol. 2017 May;4(5):e225-e236
pubmed: 28336242
Stem Cell Investig. 2016 Feb 26;3:5
pubmed: 27358897
Mol Cell. 2019 Mar 21;73(6):1292-1305.e8
pubmed: 30765193
Blood. 2019 Aug 8;134(6):568-572
pubmed: 31151988
Nat Methods. 2009 May;6(5):377-82
pubmed: 19349980
Blood. 1996 Aug 1;88(3):1013-8
pubmed: 8704209
Br J Haematol. 2014 Jun;165(6):870-82
pubmed: 24635723
N Engl J Med. 2012 Mar 1;366(9):787-98
pubmed: 22375970
Curr Opin Oncol. 2020 Mar;32(2):139-145
pubmed: 31895120
Nat Commun. 2019 Jun 3;10(1):2395
pubmed: 31160568
Hematol Oncol. 2019 Aug;37(3):240-252
pubmed: 31013548
Blood. 2013 Aug 22;122(8):1395-8
pubmed: 23838352
Blood Adv. 2019 Jan 8;3(1):83-95
pubmed: 30622146
Lancet Haematol. 2018 Feb;5(2):e73-e81
pubmed: 29275119
Lancet Haematol. 2017 Apr;4(4):e165-e175
pubmed: 28291640
Nature. 2019 May;569(7755):222-228
pubmed: 30971824
Exp Hematol. 2013 Feb;41(2):155-166.e17
pubmed: 23261964
J Clin Oncol. 2017 Dec 1;35(34):3844-3850
pubmed: 28930494
N Engl J Med. 2012 Mar 1;366(9):799-807
pubmed: 22375971
Blood. 2019 Oct 31;134(18):1498-1509
pubmed: 31515250
Oncotarget. 2016 Nov 22;7(47):78083-78094
pubmed: 27801667
Blood Cancer J. 2020 Mar 10;10(3):36
pubmed: 32157091
Nat Cell Biol. 2019 Jan;21(1):2-8
pubmed: 30602765
Curr Hematol Malig Rep. 2019 Oct;14(5):460-468
pubmed: 31372878
Blood. 2017 Aug 31;130(9):1125-1131
pubmed: 28674026
Blood. 2019 Feb 21;133(8):790-794
pubmed: 30602619
N Engl J Med. 2015 Sep 3;373(10):908-19
pubmed: 26332545
Blood. 2019 Mar 28;133(13):1427-1435
pubmed: 30728145
N Engl J Med. 2015 Jan 29;372(5):426-35
pubmed: 25629741
J Clin Oncol. 2018 Jun 10;36(17):1769-1770
pubmed: 29708808
Br J Haematol. 2020 Oct;191(2):152-170
pubmed: 32196650
Leukemia. 2018 Jul;32(7):1631-1642
pubmed: 29654267
Blood. 2010 Mar 4;115(9):1703-8
pubmed: 20008785
Blood. 2019 May 16;133(20):2233-2242
pubmed: 30760453
J Clin Oncol. 2011 Feb 1;29(4):392-7
pubmed: 21149668
Eur J Immunol. 2019 Sep;49(9):1372-1379
pubmed: 31149730
Blood. 2019 May 16;133(20):2118-2120
pubmed: 31097535
Br J Haematol. 2020 Oct;191(1):21-36
pubmed: 32167592
Nat Methods. 2020 Jan;17(1):1
pubmed: 31907477
Leukemia. 2017 Dec;31(12):2726-2731
pubmed: 28561069
Haematologica. 2018 Jan;103(1):e10-e12
pubmed: 28983061
Cell. 2019 Jun 13;177(7):1915-1932.e16
pubmed: 31130381
Nat Med. 2014 Apr;20(4):398-407
pubmed: 24658077
Ann Hematol. 2018 Mar;97(3):435-441
pubmed: 29189896
JAMA Oncol. 2018 May 1;4(5):652-659
pubmed: 29522138
Bone Marrow Transplant. 2019 Feb;54(2):204-211
pubmed: 29795431
N Engl J Med. 2019 Apr 25;380(17):1628-1637
pubmed: 31018069
Biol Blood Marrow Transplant. 2019 Jun;25(6):1142-1151
pubmed: 30625392
Lancet Haematol. 2020 Mar;7(3):e196-e208
pubmed: 32014125
Leuk Res. 2011 Jan;35(1):8-11
pubmed: 20692036
Br J Haematol. 2018 Dec;183(5):835-838
pubmed: 29265333
Cancer Cell. 2015 Jul 13;28(1):15-28
pubmed: 26175413
Haematologica. 2019 Sep;104(9):1782-1788
pubmed: 30733269
Mol Cell. 2020 May 7;78(3):477-492.e8
pubmed: 32386542
Lancet Haematol. 2017 Jul;4(7):e317-e324
pubmed: 28602585
Haematologica. 2016 May;101(5):541-58
pubmed: 27132280
EBioMedicine. 2019 Dec;50:111-121
pubmed: 31761618
JAMA Oncol. 2015 Aug;1(5):643-51
pubmed: 26181658